<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01561781</url>
  </required_header>
  <id_info>
    <org_study_id>D4200C00100</org_study_id>
    <nct_id>NCT01561781</nct_id>
  </id_info>
  <brief_title>Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib</brief_title>
  <acronym>Vandetanib</acronym>
  <official_title>A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With a Single Dose of Vandetanib (CAPRELSA) 300 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      This is a study in healthy volunteers to assess the pharmacokinetics (PK) of Digoxin
      administered alone and in combination with Vandetanib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Digoxin in
      Healthy Subjects When Administered Alone and in Combination with a Single Dose of Vandetanib
      (CAPRELSA) 300 mg
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC for digoxin administered alone and in combination with vandetanib 300 mg</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12, 18, 30, 48, 72, 96, 120, 144, and 168 hrs post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for digoxin administered alone and in combination with vandetanib 300 mg</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12, 18, 30, 48, 72, 96, 120, 144, and 168 hrs post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Treatment period + 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG data</measure>
    <time_frame>Treatment period + 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory data</measure>
    <time_frame>Treatment period + 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs data</measure>
    <time_frame>Treatment period + 7-14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK parameters for digoxin administered alone and in combination with vandetanib 300 mg</measure>
    <time_frame>Predose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12, 18, 30, 48, 72, 96, 120, 144, and 168 hrs post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digoxin PK parameters for vandetanib in combination with digoxin</measure>
    <time_frame>Predose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 48, 72, and 96 hrs post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>digoxin then digoxin + vandetanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Digoxin alone followed by digoxin in combination with vandetanib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>Oral tablets 0.25mg, single dose</description>
    <arm_group_label>digoxin then digoxin + vandetanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib</intervention_name>
    <description>Oral tablets, 300 mg, single dose</description>
    <arm_group_label>digoxin then digoxin + vandetanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study

          -  specific procedures Volunteers must be males or females aged 18 to 45 years and with a
             weight of at least 50 kg and body mass index (BMI) between 18 and 30 kg/m2,

          -  inclusive Females must have a negative pregnancy test at screening and on admission to
             the study center. Females must not be lactating and must be of non-childbearing
             potential defined as postmenopausal or documentation of irreversible surgical
             sterilization.

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder such as gastrointestinal,
             hepatic, renal or skin disease.

          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity,

          -  Volunteers who are current smokers and have smoked or used nicotine products within
             the previous 6 months

          -  Screening blood pressure of greater than 140/90 mmHg and/or a resting heart rate of
             less than 45 beats per minute (repeat test allowed at the Investigator's discretion

          -  Clinically significant abnormal12-lead ECG as assessed by the Investigator, QTcF
             interval greater than 450 ms

          -  Any positive result on screening for serum hepatitis B surface antigen, hepatitis C
             antibody, and human immunodeficiency virus (HIV), or positive screen for drugs of
             abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1435&amp;filename=CSR-D4200C00100.pdf</url>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=1435&amp;filename=CSR-D4200C00100.pdf</url>
    <description>CSR-D4200C00100.pdf</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1435&amp;filename=D4200C00100_Revised_CSP_redacted.pdf</url>
    <description>Revised_CSP_redacted</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2012</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>vandetanib</keyword>
  <keyword>digoxin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

